Literature DB >> 30316610

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.

Gwenaëlle Gravis1, Emilien Billon2, Capucine Baldini3, Christophe Massard3, Werner Hilgers4, Remy Delva5, Jochen Walz6, Geraldine Pignot6, Stanislas Rybikowski6, Slimane Dermeche2, Jeanne Thomassin7, Serge Brunelle8, Pernelle Lavaud9, Yohann Loriot9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30316610     DOI： 10.1016/j.ejca.2018.09.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma.

Authors:  Nobuki Furubayashi; Takahito Negishi; Akihiro Miura; Nobutaka Nakamura; Motonobu Nakamura
Journal:  Res Rep Urol       Date:  2020-10-09

2.  Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Authors:  Joohyun Hong; Hyun Hwan Sung; Byong Chang Jeong; Se Hoon Park
Journal:  Biomedicines       Date:  2022-08-18

3.  Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Authors:  Melissa Bersanelli; Sebastiano Buti; Alessio Cortellini; Marco Bandini; Giuseppe Luigi Banna; Filippo Pederzoli; Elena Farè; Daniele Raggi; Patrizia Giannatempo; Ugo De Giorgi; Umberto Basso; Tania Losanno; Daniele Santini; Claudia Mucciarini; Marcello Tucci; Rosa Tambaro; Azzurra Farnesi; Orazio Caffo; Antonello Veccia; Emanuele Naglieri; Alberto Briganti; Giuseppe Procopio; Sandro Pignata; Andrea Necchi
Journal:  Clin Med Insights Oncol       Date:  2021-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.